Tags

Type your tag names separated by a space and hit enter

The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses.
Immunol Cell Biol. 2022 04; 100(4):250-266.IC

Abstract

The ongoing coronavirus disease 2019 (COVID-19) pandemic perpetuated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has highlighted the continued need for broadly protective vaccines that elicit robust and durable protection. Here, the vaccinia virus-based, replication-defective Sementis Copenhagen Vector (SCV) was used to develop a first-generation COVID-19 vaccine encoding the spike glycoprotein (SCV-S). Vaccination of mice rapidly induced polyfunctional CD8 T cells with cytotoxic activity and robust type 1 T helper-biased, spike-specific antibodies, which are significantly increased following a second vaccination, and contained neutralizing activity against the alpha and beta variants of concern. Longitudinal studies indicated that neutralizing antibody activity was maintained up to 9 months after vaccination in both young and middle-aged mice, with durable immune memory evident even in the presence of pre-existing vector immunity. Therefore, SCV-S vaccination has a positive immunogenicity profile, with potential to expand protection generated by current vaccines in a heterologous boost format and presents a solid basis for second-generation SCV-based COVID-19 vaccine candidates incorporating additional SARS-CoV-2 immunogens.

Links

Authors+Show Affiliations

Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.

Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.

Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.

Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.

Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.

Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.

Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.

Guzman-Genuino RM

Sementis Limited, Hackney, SA, Australia.

Sementis Limited, Hackney, SA, Australia.

Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia. Sementis Limited, Hackney, SA, Australia.

Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia. Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.

Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia. Sementis Limited, Hackney, SA, Australia.

MeSH

AnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesHumansImmunity, CellularImmunity, HumoralMiceSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationVaccinia

Pub Type(s)

Journal Article

Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

35188985

Citation

Eldi, Preethi, et al. "The Vaccinia-based Sementis Copenhagen Vector Coronavirus Disease 2019 Vaccine Induces Broad and Durable Cellular and Humoral Immune Responses." Immunology and Cell Biology, vol. 100, no. 4, 2022, pp. 250-266.

Eldi P, Cooper TH, Prow NA, et al. The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses. Immunol Cell Biol. 2022;100(4):250-266.

Eldi, P., Cooper, T. H., Prow, N. A., Liu, L., Heinemann, G. K., Zhang, V. J., Trinidad, A. D., Guzman-Genuino, R. M., Wulff, P., Hobbs, L. M., Diener, K. R., & Hayball, J. D. (2022). The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses. Immunology and Cell Biology, 100(4), 250-266. https://doi.org/10.1111/imcb.12539

Eldi P, et al. The Vaccinia-based Sementis Copenhagen Vector Coronavirus Disease 2019 Vaccine Induces Broad and Durable Cellular and Humoral Immune Responses. Immunol Cell Biol. 2022;100(4):250-266. PubMed PMID: 35188985.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses. AU - Eldi,Preethi, AU - Cooper,Tamara H, AU - Prow,Natalie A, AU - Liu,Liang, AU - Heinemann,Gary K, AU - Zhang,Voueleng J, AU - Trinidad,Abigail D, AU - Guzman-Genuino,Ruth Marian, AU - Wulff,Peter, AU - Hobbs,Leanne M, AU - Diener,Kerrilyn R, AU - Hayball,John D, Y1 - 2022/03/13/ PY - 2022/01/10/revised PY - 2022/02/15/revised PY - 2021/09/22/received PY - 2022/02/18/accepted PY - 2022/2/22/pubmed PY - 2022/4/5/medline PY - 2022/2/21/entrez KW - Antibodies KW - COVID-19 KW - SARS-CoV-2 KW - cellular responses KW - polyfunctional T cells KW - spike KW - vaccine SP - 250 EP - 266 JF - Immunology and cell biology JO - Immunol Cell Biol VL - 100 IS - 4 N2 - The ongoing coronavirus disease 2019 (COVID-19) pandemic perpetuated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has highlighted the continued need for broadly protective vaccines that elicit robust and durable protection. Here, the vaccinia virus-based, replication-defective Sementis Copenhagen Vector (SCV) was used to develop a first-generation COVID-19 vaccine encoding the spike glycoprotein (SCV-S). Vaccination of mice rapidly induced polyfunctional CD8 T cells with cytotoxic activity and robust type 1 T helper-biased, spike-specific antibodies, which are significantly increased following a second vaccination, and contained neutralizing activity against the alpha and beta variants of concern. Longitudinal studies indicated that neutralizing antibody activity was maintained up to 9 months after vaccination in both young and middle-aged mice, with durable immune memory evident even in the presence of pre-existing vector immunity. Therefore, SCV-S vaccination has a positive immunogenicity profile, with potential to expand protection generated by current vaccines in a heterologous boost format and presents a solid basis for second-generation SCV-based COVID-19 vaccine candidates incorporating additional SARS-CoV-2 immunogens. SN - 1440-1711 UR - https://www.unboundmedicine.com/medline/citation/35188985/The_vaccinia_based_Sementis_Copenhagen_Vector_coronavirus_disease_2019_vaccine_induces_broad_and_durable_cellular_and_humoral_immune_responses_ DB - PRIME DP - Unbound Medicine ER -